When the Department of Justice announced on April 23 that cannabis would be reclassified from Schedule I to Schedule III under the Controlled Substances Act, cannabis stocks surged - and then largely gave back those gains once investors absorbed the fine print. The reclassification applies to medical marijuana, not adult-use sales, which left much of the sector's revenue base outside the immediate benefit. For two multi-state operators with concentrated exposure to medical-cannabis-only states, however, the financial implications are anything but abstract.
280E: The Tax Burden That Reshaped Cannabis Operator Economics
To understand what reclassification actually means for a licensed cannabis business, you need to start with IRS Code Section 280E. Written decades before state-legal cannabis markets existed, 280E bars businesses that "traffic" in Schedule I or II controlled substances from deducting ordinary business expenses on their federal returns. In practice, that means a dispensary operator cannot deduct payroll, rent, marketing, utilities, or most other standard costs - expenses that every other retail business in America writes off as a matter of course.
The result has been effective federal tax rates running anywhere from 60% to 70% for high-volume cannabis retailers. That's not a rounding error. It's the difference between a company that can reinvest in store expansion, supply chain infrastructure, or brand development and one that is perpetually cash-constrained despite strong gross revenue. Multi-state operators with dense retail footprints have carried this burden the hardest, because the more sales volume flowing through a dispensary network, the larger the 280E exposure.
Reclassification to Schedule III removes that bar. The federal government has confirmed that businesses no longer trafficking in Schedule I or II substances will be permitted to claim standard deductions and credits. For medical cannabis operators, that shift is immediate and material - dropping effective tax rates toward the standard corporate rate of around 21%.
Trulieve: High-Volume Medical Retail, Significant Tax Relief
Trulieve Cannabis has built one of the densest single-state retail networks in the U.S. cannabis industry, with 169 locations in Florida - a medical-cannabis-only state. That concentration made the company one of the sector's most profitable operators by adjusted EBITDA, but also one of the most exposed to 280E's blunt arithmetic. In 2025, the company reported revenue of $1.2 billion and a record adjusted EBITDA of $427 million, up 2% year over year. Those are strong operating numbers. The problem was always what happened below the EBITDA line, where the tax bill arrived.
The company has not been passive about 280E. It filed amended federal returns for 2019, 2020, and 2021, projecting $143 million in federal refunds and $31 million in state tax refunds. Those refunds are not guaranteed - the legal challenge to 280E remains unresolved - but the filings signal that Trulieve's finance and legal teams have been positioning for this regulatory shift for years. With reclassification now in effect for medical cannabis, the forward-looking picture changes significantly. Deducting ordinary business expenses from medical marijuana revenue could bring the effective tax rate from the 60-70% range down to roughly 21%, redirecting a substantial portion of operating cash toward store operations, debt service, or expansion capital.
There's a longer-term variable in Florida worth watching. A proposed constitutional amendment that would have opened the state to adult-use sales did not qualify for the 2026 ballot, according to state officials as of February. That delays a potential revenue inflection, but it doesn't eliminate it. If Florida does eventually move to adult-use, Trulieve's existing retail infrastructure - trained staff, established compliance systems, vendor relationships, and brand recognition - positions it better than any new entrant. First-mover advantage in a recreational transition is real, particularly in a state with Florida's consumer base.
Green Thumb: Institutional-Grade Financials in a Sector Short on Them
Green Thumb Industries operates differently from most of its multi-state peers in one financially meaningful way: it reports positive GAAP net income. Not adjusted EBITDA, not pro forma earnings with a long list of add-backs - actual net income under standard accounting rules, even under the old 280E regime. In a sector where "profitable" often requires an asterisk, that distinction matters to institutional investors and to anyone doing serious credit analysis on the company.
In 2025, Green Thumb reported revenue of $1.2 billion, up 3.4%, with earnings per share of $0.48 - a 60% increase year over year. The company has 110 retail outlets, including 19 dispensaries in Pennsylvania and 22 in Florida, two states currently operating as medical-only markets. With 280E relief now applicable to medical sales, those margins are expected to expand further, adding capacity for capital allocation that goes beyond just servicing the tax burden.
What's striking about Green Thumb's current position is the share repurchase program. On April 23 - the same day as the reclassification announcement - the company's board authorized an additional $100 million for buybacks, bringing the total authorized amount to $150 million. The company already repurchased 7.7 million shares in 2025 at a cost of roughly $39 million. Buybacks in any industry signal that management believes the stock is undervalued; in cannabis, where capital preservation has been a survival imperative for years, an active repurchase program is a fairly direct statement about balance sheet confidence. The Rythm brand, positioned as the No. 1 cannabis flower brand in the U.S. by the company, adds a wholesale and brand licensing dimension that extends Green Thumb's market presence beyond its own dispensary count.
What Operators and Investors Should Watch Next
The June 29 DEA hearing is the next inflection point. That proceeding could determine whether adult-use cannabis sales are also reclassified to Schedule III - which would extend 280E relief to the full revenue base of every multi-state operator, not just medical sales. For companies like Trulieve and Green Thumb, that would be a second, larger wave of margin expansion on top of what medical reclassification already delivers. The outcome is genuinely uncertain, and the DEA's hearing process is not a rubber stamp.
The broader operational implication for dispensary operators is this: reclassification doesn't change what's on the shelf, how products are tested, how inventory is tracked through seed-to-sale systems, or how compliance logs are maintained at the store level. State-level licensing requirements, lab testing and COA documentation, compliant packaging mandates, age verification protocols - all of that remains fully in force. What changes is the tax treatment of the revenue those operations generate, and for medical cannabis operators, that change is both real and immediate.
For investors who have historically priced cannabis stocks on EBITDA multiples because GAAP earnings were structurally suppressed by 280E, the calculus is shifting. Green Thumb's GAAP profitability under the old rules makes it easier to underwrite; Trulieve's potential margin recovery under reclassification is larger in percentage terms, but the starting position carries more execution risk. Neither is a simple trade. What they share is genuine, mechanism-driven exposure to a regulatory change - which, in this sector, is rarer than it sounds.
